Cargando…
K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value
Non-small-cell lung cancer (NSCLC) is a heterogeneous disease due to the presence of different clinically relevant molecular subtypes. Until today, several biological events have been identified in lung adenocarcinoma, including epidermal growth factor receptor (EGFR) mutations and anaplastic lympho...
Autores principales: | D'Arcangelo, Manolo, Cappuzzo, Federico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890888/ https://www.ncbi.nlm.nih.gov/pubmed/27398239 http://dx.doi.org/10.5402/2012/837306 |
Ejemplares similares
-
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2013) -
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021) -
Clinical and comparative utility of afatinib in non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2014) -
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
por: Vecchiarelli, Silvia, et al.
Publicado: (2018) -
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2019)